Select Region or Location
Americas
  • Argentina
  • Brazil
  • Canada
  • Mexico
  • United States
  • Other Americas
Europe
  • Austria
  • Belgium
  • Bulgaria
  • Croatia/Hrvatska
  • Cyprus
  • Czech Republic
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Ireland
  • Italy
  • Latvia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Malta
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovak Republic
  • Slovenia
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Kingdom
  • Other Europe
Asia Pacific
  • Australia
  • China
  • India
  • Indonesia
  • Japan
  • Korea, Republic of
  • Malaysia
  • New Zealand
  • Philippines
  • Singapore
  • Thailand
  • Vietnam
  • Other Asia Pacific
Africa And Middle East
  • Egypt
  • Israel
  • Other Africa And Middle East
USD
Home Cart Sign in  
Chemical Structure| 856418-53-6 Chemical Structure| 856418-53-6
Chemical Structure| 856418-53-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only! Not for Human Use. We Do Not Sell to Patients.

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]}{[ size_append_text(item.pr_size, proInfo.prAm, 'list') ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}
    {[ size_append_text(item.pr_size, proInfo.prAm, 'list') ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details

CAS No. :856418-53-6
Formula : C14H25N3O3
M.W : 283.37
SMILES Code : O=C(N1CC(N(C2CCNCC2)CC1)=O)OC(C)(C)C
English Name :tert-Butyl 3-oxo-4-(piperidin-4-yl)piperazine-1-carboxylate
MDL No. :MFCD29046338

Safety

Application In Synthesis

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 856418-53-6 ]

[ 856418-53-6 ] Synthesis Path-Downstream   1~2

  • 1
  • [ 856418-53-6 ]
  • [ 70874-05-4 ]
  • [ 856418-54-7 ]
YieldReaction ConditionsOperation in experiment
100% Stage #1: Z-D-Tle With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In acetonitrile at 20℃; for 0.25h; Stage #2: tert-butyl 3-oxo-4-(4-piperidinyl)-1-piperazinecarboxylate With triethylamine at 20℃; for 15h; 103.b 103b) 103b) tert-butyl 4-((2R)-2-(benzyloxycarbonylamino)-3,3-dimethylbutyroyl)-4-piperidinyl)-3-oxo-1-piperazinecarboxylate To a solution of Z-D-tert-leucine (0.64 g) and HOBt (0.55 g) in acetonitrile (20 ml) was added WSC (0.69 g), and the reaction mixture was mixed at room temperature for 15 minutes. Then, tert-butyl 3-oxo-4-(4-piperidinyl)-1-piperazinecarboxylate (0.68 g) obtained in Example 103a) and triethylamine (0.73 g) were added thereto. The reaction mixture was mixed at room temperature for 15 hours, and then the solvent was distilled off under reduced pressure. The residue was dissolved in ethyl acetate, and the reaction mixture was washed sequentially with an aqueous sodium hydrogen carbonate solution, water, a 5% aqueous citric acid solution and saturated brine and dried over anhydrous sodium sulfate. Then, the solvent was distilled off under reduced pressure, and the residue was purified with silica gel column (ethyl acetate) to obtain the title compound as a colorless oil (1.3 g, quantitative). NMR (CDCl3) δ: 0.98-1.01 (9H, m), 1.47 (9H, s), 1.56-1.78 (4H, m), 2.59-2.68 (1H, m), 3.12-3.22 (3H, m), 3.53-3.62 (2H, m), 4.09-4.23 (3H, m), 4.56-4.59 (1H, m), 4.71-4.75 (2H, m), 5.09-5.10 (2H, m), 5.55-5.60 (1H, m), 7.35-7.37 (5H, m).
  • 2
  • [ 856418-53-6 ]
  • [ 2758532-18-0 ]
  • [ 2934804-99-4 ]
YieldReaction ConditionsOperation in experiment
88.7 % With RuPhos Pd G3; caesium carbonate In 1,4-dioxane at 20 - 100℃; Inert atmosphere; 425.2 Step 2: tert-butyl 4- (1- (4- (2, 6-bis (benzyloxy) pyridin-3-yl) -3,5-difluorophenyl) piperidin-4-yl) -3-oxopiperazine-1-carboxylate [1573] [1574] To a stirred solution of tert-butyl 3-oxo-4- (piperidin-4-yl) piperazine-1-carboxylate (0.7 g, 2.47 mmol) and 2, 6-bis (benzyloxy)-3-(4-bromo-2,6-difluorophenyl) pyridine (1.2 g, 2.27 mmol) in dioxane (20 mL) were added Cs 2CO 3 (1.16 g, 4.94 mmol) and Ruphos Pd G3 (0.2 g, 0.25 mmol) at room temperature under nitrogen atmosphere. The resulting mixture was stirred for 16 h at 100 °C under nitrogen atmosphere. The mixture was allowed to cool down to room temperature. The resulting mixture was concentrated under reduced pressure. The residue was diluted with EtOAc (200 mL), washed with water (3 x 100 mL) and brine (100 mL). The organic layer was dried over anhydrous Na 2SO 4, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE/EtOAc (4: 1) to afford the product (1.5 g, 88.7%) ; [M+H] + = 685.1.
88.7 % With RuPhos Pd G3; caesium carbonate In 1,4-dioxane at 20 - 100℃; Inert atmosphere; 425.2 Step 2: tert-butyl 4- (1- (4- (2, 6-bis (benzyloxy) pyridin-3-yl) -3,5-difluorophenyl) piperidin-4-yl) -3-oxopiperazine-1-carboxylate [1573] [1574] To a stirred solution of tert-butyl 3-oxo-4- (piperidin-4-yl) piperazine-1-carboxylate (0.7 g, 2.47 mmol) and 2, 6-bis (benzyloxy)-3-(4-bromo-2,6-difluorophenyl) pyridine (1.2 g, 2.27 mmol) in dioxane (20 mL) were added Cs 2CO 3 (1.16 g, 4.94 mmol) and Ruphos Pd G3 (0.2 g, 0.25 mmol) at room temperature under nitrogen atmosphere. The resulting mixture was stirred for 16 h at 100 °C under nitrogen atmosphere. The mixture was allowed to cool down to room temperature. The resulting mixture was concentrated under reduced pressure. The residue was diluted with EtOAc (200 mL), washed with water (3 x 100 mL) and brine (100 mL). The organic layer was dried over anhydrous Na 2SO 4, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE/EtOAc (4: 1) to afford the product (1.5 g, 88.7%) ; [M+H] + = 685.1.
16.9 % With tris-(dibenzylideneacetone)dipalladium(0); caesium carbonate; ruphos In N,N-dimethyl acetamide at 100℃; Inert atmosphere; Step 1: tert-butyl 4-(1-(4-(2,6-bis(benzyloxy)pyridin-3-yl)-3,5-difluorophenyl)piperidin-4-yl)-3- oxopiperazine-1-carboxylate O F OBn To a stirred solution of intermediate 6 (1.5 g, 3.1 mmol) and tert-butyl 3-oxo-4-(piperidin-4-yl)piperazine-1- carboxylate (1.2 g, 4.2 mmol) in DMA (30 mL) were added Cs2CO3(3.17 g, 9.75 mmol), Pd2(dba)3(300 mg, 0.325 mmol) and Ruphos (300 mg, 0.65 mmol) at room temperatureunder nitrogenatmosphere. The resulting mixture was stirred for 16 h at 100 Cunder nitrogenatmosphere. The mixture was allowed to cool down to room temperature. The resulting mixture was concentrated under reduced pressure. The residue was diluted with EtOAc (200 mL), washed with water (3 x 100 mL) and brine (100 mL). The organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE/EtOAc (4:1) to afford the product (360 mg, 16.9%); [M+H]+= 685.7.
 

Historical Records

Categories